Philip Toleikis, Ph.D., President and CEO

Oct. 11 | 3:00pm | UBC Ballroom  

Ontario, Canada 


In-person Presentation 

Sernova is a clinical-stage biotechnology company developing regenerative therapeutic technologies to deliver a functional cure for chronic diseases, including insulin-dependent diabetes, thyroid disease, and rare diseases like Hemophilia A. An ongoing Phase I/II study at the University of Chicago using Sernova’s Cell Pouch implantable device and human donor islets has provided positive interim data. The first two subjects in the study have achieved long term insulin independence. To provide an unlimited supply of cells to treat type 1 diabetes, Sernova and Evotec recently entered into an option and licensing partnership developing an off-the-shelf iPSC-based beta cell replacement therapy.

By using this website you agree to accept our Privacy Policy and Terms & Conditions